{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:57:06Z","timestamp":1787320626194,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["15741"],"award-info":[{"award-number":["15741"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15905-7","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:34:06Z","timestamp":1774514046000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interactive symptom monitoring and coaching to optimise toxicity management of chemo(immune)therapy in early stage breast cancer: study protocol of the multicentre randomised controlled eChemoCoach trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Rubin J. T.","family":"Verduin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina J. G.","family":"van den Hurk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid S.","family":"van Maurik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke M.","family":"Nota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Elise","family":"van Leeuwen-Stok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon M. C.","family":"Komen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance H. C.","family":"Drossaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Siesling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathijs P.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"15905_CR1","doi-asserted-by":"publisher","unstructured":"Basak D, Arrighi S, Darwiche Y, Deb S. Comparison of anticancer drug toxicities: paradigm shift in adverse effect profile. Life (Basel). 2021;12(1):48. https:\/\/doi.org\/10.3390\/life12010048.","DOI":"10.3390\/life12010048"},{"issue":"4","key":"15905_CR2","doi-asserted-by":"publisher","first-page":"e0196007","DOI":"10.1371\/journal.pone.0196007","volume":"13","author":"W Wong","year":"2018","unstructured":"Wong W, Yim YM, Kim A, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A. Assessment of costs associated with adverse events in patients with cancer. PLoS ONE. 2018;13(4):e0196007.","journal-title":"PLoS ONE"},{"issue":"2","key":"15905_CR3","first-page":"365","volume":"19","author":"S Omran","year":"2018","unstructured":"Omran S, McMillan S. Symptom severity, anxiety, depression, self- efficacy and quality of life in patients with cancer. Asian Pac J Cancer Prev. 2018;19(2):365\u201374.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"9","key":"15905_CR4","doi-asserted-by":"publisher","first-page":"e1609","DOI":"10.1002\/onco.13822","volume":"26","author":"CM Nielson","year":"2021","unstructured":"Nielson CM, Bylsma LC, Fryzek JP, Saad HA, Crawford J. Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis. Oncologist. 2021;26(9):e1609\u201318.","journal-title":"Oncologist"},{"issue":"1","key":"15905_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1188\/17.ONF.31-43","volume":"44","author":"MN Neuss","year":"2017","unstructured":"Neuss MN, Gilmore TR, Belderson KM, Billett AL, Conti-Kalchik T, Harvey BE, et al. 2016 Updated American society of clinical oncology\/oncology nursing society chemotherapy administration safety standards, including standards for pediatric oncology. Oncol Nurs Forum. 2017;44(1):31\u201343.","journal-title":"Oncol Nurs Forum"},{"issue":"8","key":"15905_CR6","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","volume":"33","author":"M Di Maio","year":"2015","unstructured":"Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, et al. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol. 2015;33(8):910\u20135.","journal-title":"J Clin Oncol"},{"issue":"11","key":"15905_CR7","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1470-2045(06)70910-X","volume":"7","author":"E Basch","year":"2006","unstructured":"Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, et al. Patient versus clinician symptom reporting using the national cancer institute common terminology criteria for adverse events: results of a questionnaire-based study. Lancet Oncol. 2006;7(11):903\u20139.","journal-title":"Lancet Oncol"},{"key":"15905_CR8","doi-asserted-by":"publisher","first-page":"e49089","DOI":"10.2196\/49089","volume":"26","author":"MB Perry","year":"2024","unstructured":"Perry MB, Taylor S, Khatoon B, Vercell A, Faivre-Finn C, Velikova G, et al. Examining the effectiveness of electronic patient-reported outcomes in people with cancer: systematic review and meta-analysis. J Med Internet Res. 2024;26:e49089.","journal-title":"J Med Internet Res"},{"issue":"4","key":"15905_CR9","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41591-025-03507-y","volume":"31","author":"E Basch","year":"2025","unstructured":"Basch E, Schrag D, Jansen J, Henson S, Ginos B, Stover AM, et al. Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial. Nat Med. 2025;31(4):1225\u201332.","journal-title":"Nat Med"},{"key":"15905_CR10","doi-asserted-by":"publisher","first-page":"e53539","DOI":"10.2196\/53539","volume":"11","author":"M-T Crafoord","year":"2025","unstructured":"Crafoord M-T, Ekstrand J, Sundberg K, Nilsson MI, Fjell M, Langius-Ekl\u00f6f A. Mobile electronic patient-reported outcomes and interactive support during breast and prostate cancer treatment: health economic evaluation from two randomized controlled trials. JMIR Cancer. 2025;11:e53539.","journal-title":"JMIR Cancer"},{"issue":"8","key":"15905_CR11","doi-asserted-by":"publisher","first-page":"e2428975","DOI":"10.1001\/jamanetworkopen.2024.28975","volume":"7","author":"NE Billingy","year":"2024","unstructured":"Billingy NE, van den Hurk CJG, van de Poll-Franse VNMFT, Onwuteaka-Philipsen L, Hugtenburg BD. Patient- vs physician-initiated response to symptom monitoring and health-related quality of life: the SYMPRO-lung cluster randomized trial. JAMA Netw Open. 2024;7(8):e2428975.","journal-title":"JAMA Netw Open"},{"key":"15905_CR12","doi-asserted-by":"publisher","unstructured":"Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, et al. Development of the national cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):dju244. https:\/\/doi.org\/10.1093\/jnci\/dju244.","DOI":"10.1093\/jnci\/dju244"},{"issue":"7","key":"15905_CR13","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1200\/JCO.20.02015","volume":"39","author":"K Absolom","year":"2021","unstructured":"Absolom K, Warrington L, Hudson E, Hewison J, Morris C, Holch P, et al. Phase III randomized controlled trial of eRAPID: eHealth intervention during chemotherapy. J Clin Oncol. 2021;39(7):734\u201347.","journal-title":"J Clin Oncol"},{"key":"15905_CR14","doi-asserted-by":"publisher","first-page":"n1647","DOI":"10.1136\/bmj.n1647","volume":"374","author":"R Maguire","year":"2021","unstructured":"Maguire R, McCann L, Kotronoulas G, Kearney N, Ream E, Armes J, et al. Real time remote symptom monitoring during chemotherapy for cancer: European multicentre randomised controlled trial (eSMART). BMJ. 2021;374:n1647.","journal-title":"BMJ"},{"key":"15905_CR15","doi-asserted-by":"publisher","first-page":"e48483","DOI":"10.2196\/48483","volume":"25","author":"R Govindaraj","year":"2023","unstructured":"Govindaraj R, Agar M, Currow D, Luckett T. Assessing patient-reported outcomes in routine cancer clinical care using electronic administration and telehealth technologies: realist synthesis of potential mechanisms for improving health outcomes. J Med Internet Res. 2023;25:e48483.","journal-title":"J Med Internet Res"},{"issue":"11","key":"15905_CR16","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1200\/OP.23.00415","volume":"19","author":"CC O\u2019Sullivan","year":"2023","unstructured":"O\u2019Sullivan CC, Cracchiolo JR, Tevaarwerk AJ. Lessons learned and practice pearls: optimal integration of electronic patient-reported outcomes in the medical oncology clinic. JCO Oncol Pract. 2023;19(11):951\u20134.","journal-title":"JCO Oncol Pract"},{"issue":"8","key":"15905_CR17","doi-asserted-by":"publisher","first-page":"e37290","DOI":"10.2196\/37290","volume":"10","author":"M Hyzy","year":"2022","unstructured":"Hyzy M, Bond R, Mulvenna M, Bai L, Dix A, Leigh S, Hunt S. System usability scale benchmarking for digital health apps: meta-analysis. JMIR Mhealth Uhealth. 2022;10(8):e37290.","journal-title":"JMIR Mhealth Uhealth"},{"key":"15905_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejca.2017.04.001","volume":"79","author":"SJ Schraa","year":"2017","unstructured":"Schraa SJ, Frerichs KA, Agterof MJ, Hunting JCB, Los M, de Jong PC. Relative dose intensity as a proxy measure of quality and prognosis in adjuvant chemotherapy for breast cancer in daily clinical practice. Eur J Cancer. 2017;79:152\u20137.","journal-title":"Eur J Cancer"},{"issue":"5","key":"15905_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"15905_CR20","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.2196\/jmir.8210","volume":"19","author":"M Wallwiener","year":"2017","unstructured":"Wallwiener M, Matthies L, Simoes E, Keilmann L, Hartkopf AD, Sokolov AN, et al. Reliability of an e-PRO Tool of EORTC QLQ-C30 for measurement of health-related quality of life in patients with breast cancer: prospective randomized trial. J Med Internet Res. 2017;19(9):e322.","journal-title":"J Med Internet Res"},{"key":"15905_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jclinepi.2019.10.003","volume":"118","author":"JM Giesinger","year":"2020","unstructured":"Giesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F, et al. Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol. 2020;118:1\u20138.","journal-title":"J Clin Epidemiol"},{"key":"15905_CR22","doi-asserted-by":"publisher","unstructured":"Musoro JZ, Coens C, Fiteni F, Katarzyna P, Cardoso F, Russell NS, et al. Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced breast cancer. JNCI Cancer Spectr. 2019;3(3):pkz037. https:\/\/doi.org\/10.1093\/jncics\/pkz037.","DOI":"10.1093\/jncics\/pkz037"},{"issue":"6","key":"15905_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361\u201370.","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"15905_CR24","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/sj.bjc.6604952","volume":"100","author":"S Singer","year":"2009","unstructured":"Singer S, Kuhnt S, G\u00f6tze H, Hauss J, Hinz A, Liebmann A, et al. Hospital anxiety and depression scale cutoff scores for cancer patients in acute care. Br J Cancer. 2009;100(6):908\u201312.","journal-title":"Br J Cancer"},{"issue":"1","key":"15905_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1477-7525-6-46","volume":"6","author":"MA Puhan","year":"2008","unstructured":"Puhan MA, Frey M, B\u00fcchi S, Sch\u00fcnemann HJ. The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2008;6(1):46.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"15905_CR26","doi-asserted-by":"publisher","first-page":"E6","DOI":"10.1097\/HCR.0000000000000379","volume":"39","author":"KR Lemay","year":"2019","unstructured":"Lemay KR, Tulloch HE, Pipe AL, Reed JL. Establishing the minimal clinically important difference for the hospital anxiety and depression scale in patients with cardiovascular disease. J Cardiopulm Rehabil Prev. 2019;39(6):E6\u201311.","journal-title":"J Cardiopulm Rehabil Prev"},{"issue":"29","key":"15905_CR27","doi-asserted-by":"publisher","first-page":"4670","DOI":"10.1200\/JCO.2006.10.0438","volume":"25","author":"AJ Mitchell","year":"2007","unstructured":"Mitchell AJ. Pooled results from 38 analyses of the accuracy of distress thermometer and other ultra-short methods of detecting cancer-related mood disorders. J Clin Oncol. 2007;25(29):4670\u201381.","journal-title":"J Clin Oncol"},{"issue":"4","key":"15905_CR28","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/pon.1917","volume":"21","author":"PE Bidstrup","year":"2012","unstructured":"Bidstrup PE, Mertz BG, Dalton SO, Deltour I, Kroman N, Kehlet H, et al. Accuracy of the Danish version of the \u2018distress thermometer\u2019. Psychooncology. 2012;21(4):436\u201343.","journal-title":"Psychooncology"},{"issue":"15suppl","key":"15905_CR29","doi-asserted-by":"publisher","first-page":"e24200","DOI":"10.1200\/JCO.2020.38.15_suppl.e24200","volume":"38","author":"F Ullah","year":"2020","unstructured":"Ullah F, Brugioni E, Gannon MM, Smith HL, Lukenbill JC. Longitudinal investigation of distress thermometer scores in patients with cancer. J Clin Oncol. 2020;38(15suppl):e24200\u2013e.","journal-title":"J Clin Oncol"},{"key":"15905_CR30","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1186\/1471-2458-12-577","volume":"12","author":"J Rademakers","year":"2012","unstructured":"Rademakers J, Nijman J, van der Hoek L, Heijmans M, Rijken M. Measuring patient activation in The Netherlands: translation and validation of the American short form Patient Activation Measure (PAM13). BMC Public Health. 2012;12:577.","journal-title":"BMC Public Health"},{"issue":"2","key":"15905_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qualitative Res Psychol"},{"issue":"3","key":"15905_CR32","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/bimj.201700067","volume":"60","author":"G Heinze","year":"2018","unstructured":"Heinze G, Wallisch C, Dunkler D. Variable selection - a review and recommendations for the practicing statistician. Biom J. 2018;60(3):431\u201349.","journal-title":"Biom J"},{"issue":"3","key":"15905_CR33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/1740774517698645","volume":"14","author":"TR Mendoza","year":"2017","unstructured":"Mendoza TR, Dueck AC, Bennett AV, Mitchell SA, Reeve BB, Atkinson TM, et al. Evaluation of different recall periods for the US National Cancer Institute\u2019s PRO-CTCAE. Clin Trials. 2017;14(3):255\u201363.","journal-title":"Clin Trials"},{"key":"15905_CR34","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2021.07.033","volume":"156","author":"V M\u00f6bus","year":"2021","unstructured":"M\u00f6bus V, L\u00fcck HJ, Ladda E, Klare P, Schmidt M, Schneeweiss A, et al. Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). Eur J Cancer. 2021;156:138\u201348.","journal-title":"Eur J Cancer"},{"issue":"12","key":"15905_CR35","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","volume":"19","author":"MS van Ramshorst","year":"2018","unstructured":"van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentje VO, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1630\u201340.","journal-title":"Lancet Oncol"},{"issue":"1","key":"15905_CR36","doi-asserted-by":"publisher","first-page":"160018","DOI":"10.1038\/sdata.2016.18","volume":"3","author":"MD Wilkinson","year":"2016","unstructured":"Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, et al. The fair guiding principles for scientific data management and stewardship. Sci Data. 2016;3(1):160018.","journal-title":"Sci Data"},{"issue":"1","key":"15905_CR37","doi-asserted-by":"publisher","first-page":"e10875","DOI":"10.2196\/10875","volume":"21","author":"L Warrington","year":"2019","unstructured":"Warrington L, Absolom K, Conner M, Kellar I, Clayton B, Ayres M, Velikova G. Electronic systems for patients to report and manage side effects of cancer treatment: systematic review. J Med Internet Res. 2019;21(1):e10875.","journal-title":"J Med Internet Res"},{"key":"15905_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2147\/PROM.S256567","volume":"13","author":"LM Minasian","year":"2022","unstructured":"Minasian LM, O\u2019Mara A, Mitchell SA. Clinician and patient reporting of symptomatic adverse events in cancer clinical trials: using CTCAE and PRO-CTCAE(\u00ae) to provide two distinct and complementary perspectives. Patient Relat Outcome Meas. 2022;13:249\u201358.","journal-title":"Patient Relat Outcome Meas"},{"issue":"9","key":"15905_CR39","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.annonc.2022.04.007","volume":"33","author":"M Di Maio","year":"2022","unstructured":"Di Maio M, Basch E, Denis F, Fallowfield LJ, Ganz PA, Howell D, et al. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline. Ann Oncol. 2022;33(9):878\u201392.","journal-title":"Ann Oncol"},{"key":"15905_CR40","first-page":"e2200187","volume":"7","author":"E Basch","year":"2023","unstructured":"Basch E, Rocque G, Mody G, Mullangi S, Patt D. Tenets for implementing electronic patient-reported outcomes for remote symptom monitoring during cancer treatment. JCO Clin Cancer Inf. 2023;7:e2200187.","journal-title":"JCO Clin Cancer Inf"},{"key":"15905_CR41","doi-asserted-by":"crossref","unstructured":"Aanes SG, Wiig S, Nieder C, Haukland EC. Implementing digital patient-reported outcomes in routine cancer care: barriers and facilitators. Volume 6. ESMO Real World Data and Digital Oncology; 2024.","DOI":"10.1016\/j.esmorw.2024.100088"},{"issue":"9","key":"15905_CR42","doi-asserted-by":"publisher","first-page":"e25195","DOI":"10.2196\/25195","volume":"23","author":"GM Peters","year":"2021","unstructured":"Peters GM, Kooij L, Lenferink A, van Harten WH, Doggen CJM. The effect of telehealth on hospital services use: systematic review and meta-analysis. J Med Internet Res. 2021;23(9):e25195.","journal-title":"J Med Internet Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15905-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15905-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15905-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:12:10Z","timestamp":1778022730000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15905-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15905"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15905-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complied with the Declaration of Helsinki and obtained ethical approval from the Medical Ethical Committees United (MEC-U), located in Nieuwegein, the Netherlands (R24.094). Informed consent will be obtained from all participants prior to enrolment by the local trial nurse. They will be informed that they may withdraw from the study at any time or choose not to answer specific interview questions. Participant anonymity will be maintained throughout the study and personal data will be managed in accordance with the GDPR.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"571"}}